The next generation of MMP inhibitors. Design and synthesis.
Since their inception during the eighties, MMP inhibitors (MMPIs) have gone through several cycles of metamorphosis. The design of early MMPIs was based on the cleavage site of peptide substrates. The second generation contained a substituted succinate scaffold (e.g., marimastat) coupled to a modified amino acid residue. The lower molecular weight analogs with multiple substitution possibilities produced a series of MMP inhibitors with varying degrees of selectivity for various MMPs. The introduction of sulfonamides in the midnineties added a new dimension to this field. The simplicity of synthesis coupled with high potency (e.g., CGS-27023A, AG-3340) produced a number of clinical candidates. This review highlights some of the key features that contributed to the discovery of this novel series of MMP inhibitors.
Procter & Gamble Pharmaceuticals, Mason, Ohio 45040-8006, USA.
B
B
De
M G
MG
Natchus
M
M
Cheng
S
S
Pikul
N G
NG
Almstead
Y O
YO
Taiwo
C E
CE
Snider
L
L
Chen
B
B
Barnett
F
F
Gu
M
M
Dowty
D002209:Caprolactam / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D015195:Drug Design; D005109:Extracellular Matrix / Q000201:enzymology; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors* / Q000737:chemistry; D010721:Phosphinic Acids / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D010879:Piperazines / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D011480:Protease Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology
D010721:Phosphinic Acids; D010879:Piperazines; D011480:Protease Inhibitors; D002209:Caprolactam; D008666:Metalloendopeptidases